Role of [18F]-Fluorodeoxy-D-Glucose Positron Emission Tomography and Computed Tomography in the Early Detection of Persistent/Recurrent Thyroid Carcinoma in Intermediate-to-High Risk Patients Following Initial Radioactive Iodine Ablation Therapy
Abstract
Background: Positron emission tomography/computed tomography (PET/CT) scan has a role in the surveillance of patients with a history of thyroid carcinoma. Its efficacy after remnant ablation as far as detecting persistent or recurrent thyroid carcinoma before other surveillance methods is not known, however. In intermediate-to-high risk thyroid carcinoma patients we studied whether PET/CT scan, performed 6–12 months after the first remnant ablation, could provide more information than ultrasonography (US) and thyrotropin-stimulated serum thyroglobulin (Tg) determination with diagnostic whole-body scan (DxWBS).
Methods: We studied 71 subjects with differentiated thyroid cancer (DTC) who were intermediate-to-high risk for persistent/recurrent disease and who had received PET/CT scan, US, and DxWBS simultaneously with stimulated Tg levels 6–12 months after remnant ablation. To evaluate the diagnostic efficacy of PET/CT scan, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were calculated.
Results: Ten subjects (14%) had persistent/recurrent disease detected 6–12 months after remnant ablation. Persistence/recurrence was detected in nine (12.7%) of these patients by conventional methods, including US and DxWBS, along with stimulated Tg levels. The remaining case was detected solely by a PET/CT scan, which showed a mediastinal prevascular lesion; this was confirmed by a therapeutic WBS after additional radioiodine therapy. Among the six patients whose PET/CT scan showed positive results, five had persistent/recurrent disease. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of PET/CT scan for detecting persistent/recurrent thyroid carcinoma were 50%, 98.4%, 83.3%, 92.3%, and 91.5%, respectively.
Conclusion: In intermediate-to-high risk patients with DTC seen 6–12 months after their first remnant ablation, there is almost no complementary role for adding a PET/CT scan to conventional follow-up methods, an US and a DxWBS simultaneously with stimulated Tg levels.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Jung KWPark SKong HJWon YJBoo YKShin HRPark ECLee JS2010. Cancer statistics in Korea: incidence, mortality and survival in 2006–2007J Korean Med Sci251113-1121. 1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS 2010 Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci 25:1113–1121.
2.
Hundahl SAFleming IDFremgen AMMenck HR1998. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995Cancer832638-2648. 2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648.
3.
Brierley JTsang RPanzarella TBana N2005. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 yearsClin Endocrinol (Oxf)63418-427. 3. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 63:418–427.
4.
Lin JDChao TCHsueh CKuo SF2009. High recurrent rate of multicentric papillary thyroid carcinomaAnn Surg Oncol162609-2616. 4. Lin JD, Chao TC, Hsueh C, Kuo SF 2009 High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol 16:2609–2616.
5.
Grant CSStulak JMThompson GBRichards MLReading CCHay ID2010. Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999–2006World J Surg341239-1246. 5. Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay ID 2010 Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999–2006. World J Surg 34:1239–1246.
6.
Woodrum DTGauger PG2005. Role of 131I in the treatment of well differentiated thyroid cancerJ Surg Oncol89114-121. 6. Woodrum DT, Gauger PG 2005 Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol 89:114–121.
7.
Lin JDHsueh CChao TC2009. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcomeThyroid191053-1059. 7. Lin JD, Hsueh C, Chao TC 2009 Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19:1053–1059.
8.
Cooper DSDoherty GMHaugen BRKloos RTLee SLMandel SJMazzaferri ELMcIver BPacini FSchlumberger MSherman SISteward DLTuttle RM2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid191167-1214. 8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214.
9.
Kidd EASiegel BADehdashti FGrigsby PW2007. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survivalCancer1101738-1744. 9. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2007 The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738–1744.
10.
Kornberg AFreesmeyer MBarthel EJandt KKatenkamp KSteenbeck JSappler AHabrecht OGottschild DSettmacher U2009. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patientsAm J Transplant9592-600. 10. Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U 2009 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9:592–600.
11.
Kidd EASiegel BADehdashti FGrigsby PW2010. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancerCancer1161469-1475. 11. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2010 Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 116:1469–1475.
12.
Chung JKSo YLee JSChoi CWLim SMLee DSHong SWYoun YKLee MCCho BY1999. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scanJ Nucl Med40986-992. 12. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY 1999 Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986–992.
13.
Muros MALlamas-Elvira JMRamirez-Navarro AGomez MJRodriguez-Fernandez AMuros TLopez de la Torre MBecerra ACarreras JL2000. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levelsAm J Surg179457-461. 13. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, Lopez de la Torre M, Becerra A, Carreras JL 2000 Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179:457–461.
14.
Lim D-JO JHKim M-HKim J-HKwon H-SKim S-HKang M-ICha B-YLee K-WSon H-Y2010. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulinKorean J Intern Med25408-414. 14. Lim D-J, O JH, Kim M-H, Kim J-H, Kwon H-S, Kim S-H, Kang M-I, Cha B-Y, Lee K-W, Son H-Y 2010 Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J Intern Med 25:408–414.
15.
Leboulleux SGirard ERose MTravagli JPSabbah NCaillou BHartl DMLassau NBaudin ESchlumberger M2007. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancerJ Clin Endocrinol Metab923590-3594. 15. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 92:3590–3594.
16.
Mazzaferri ELKloos RT2001. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancerJ Clin Endocrinol Metab861447-1463. 16. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463.
17.
Frasoldati APesenti MGallo MCaroggio ASalvo DValcavi R2003. Diagnosis of neck recurrences in patients with differentiated thyroid carcinomaCancer9790-96. 17. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90–96.
18.
Torlontano MAttard MCrocetti UTumino SBruno RCostante GD'Azzo GMeringolo DFerretti ESacco RArturi FFiletti S2004. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastasesJ Clin Endocrinol Metab893402-3407. 18. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402–3407.
19.
Clark OHHoelting T1994. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scansThyroid4501-505. 19. Clark OH, Hoelting T 1994 Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 4:501–505.
20.
Iagaru AKalinyak JEMcDougall IR2007. F-18 FDG PET/CT in the management of thyroid cancerClin Nucl Med32690-695. 20. Iagaru A, Kalinyak JE, McDougall IR 2007 F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32:690–695.
21.
Larson SMRobbins R2002. Positron emission tomography in thyroid cancer managementSemin Roentgenol37169-174. 21. Larson SM, Robbins R 2002 Positron emission tomography in thyroid cancer management. Semin Roentgenol 37:169–174.
22.
Robbins RJWan QGrewal RKReibke RGonen MStrauss HWTuttle RMDrucker WLarson SM2006. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanningJ Clin Endocrinol Metab91498-505. 22. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505.
23.
Frilling ATecklenborg KGorges RWeber FClausen MBroelsch EC2001. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinomaAnn Surg234804-811. 23. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC 2001 Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804–811.
24.
Yun MNoh TWCho AChoi YJHong SWPark CSLee JDKim CK. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factorJ Clin Endocrinol Metab953182-3188. 24. Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95:3182–3188.
25.
Alzahrani ASAbouzied MESalam SAMohamed GRifai AAl Sugair AAmin T2008. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancerEur J Endocrinol158683-689. 25. Alzahrani AS, Abouzied ME, Salam SA, Mohamed G, Rifai A, Al Sugair A, Amin T 2008 The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer. Eur J Endocrinol 158:683–689.
26.
Jeong HSBaek CHSon YIChoi JYKim HJKo YHChung JHBaek HJ2006. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CTClin Endocrinol (Oxf)65402-407. 26. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ 2006 Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 65:402–407.
27.
Shammas ADegirmenci BMountz JMMcCook BMBranstetter BBencherif BJoyce JMCarty SEKuffner HAAvril N2007. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancerJ Nucl Med48221-226. 27. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221–226.
28.
Kaneko KAbe KBaba SIsoda TYabuuchi HSasaki MHatakenaka MHonda H2010. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CTClin Nucl Med356-11. 28. Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, Hatakenaka M, Honda H 2010 Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med 35:6–11.
29.
Miller MEChen QElashoff DAbemayor ESt John M2010. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature reviewHead Neck33562-565. 29. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M 2010 Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck 33:562–565.
30.
Hwang HSPerez DAOrloff LA2009. Comparison of positron emission tomography/computed tomography imaging and ultrasound in staging and surveillance of head and neck and thyroid cancerLaryngoscope1191958-1965. 30. Hwang HS, Perez DA, Orloff LA 2009 Comparison of positron emission tomography/computed tomography imaging and ultrasound in staging and surveillance of head and neck and thyroid cancer. Laryngoscope 119:1958–1965.
31.
Schluter BBohuslavizki KHBeyer WPlotkin MBuchert RClausen M2001. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scanJ Nucl Med4271-76. 31. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M 2001 Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71–76.
32.
Seo JHLee SWAhn BCLee J2010. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CTClin Endocrinol (Oxf)72558-563. 32. Seo JH, Lee SW, Ahn BC, Lee J 2010 Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 72:558–563.
33.
Pacini FCapezzone MElisei RCeccarelli CTaddei DPinchera A2002. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatmentJ Clin Endocrinol Metab871499-1501. 33. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499–1501.
34.
Kim WGRyu JSKim EYLee JHBaek JHYoon JHHong SJKim ESKim TYKim WBShong YK2010. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scanJ Clin Endocrinol Metab951169-1173. 34. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK 2010 Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 95:1169–1173.
35.
Leboulleux SSchroeder PRBusaidy NLAuperin ACorone CJacene HAEwertz MEBournaud CWahl RLSherman SILadenson PWSchlumberger M2009. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancerJ Clin Endocrinol Metab941310-1316. 35. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94:1310–1316.
36.
Greven KMWilliams DW 3rdKeyes JW JrMcGuirt WFWatson NE JrRandall MERaben MGeisinger KRCappellari JO1994. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiationCancer741355-1359. 36. Greven KM, Williams DW 3rd, Keyes JW Jr, McGuirt WF, Watson NE Jr, Randall ME, Raben M, Geisinger KR, Cappellari JO 1994 Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74:1355–1359.
37.
Greven KMWilliams DW 3rdMcGuirt WF SrHarkness BAD'Agostino RB JrKeyes JW JrWatson NE Jr2001. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancerHead Neck23942-946. 37. Greven KM, Williams DW 3rd, McGuirt WF Sr, Harkness BA, D'Agostino RB Jr, Keyes JW Jr, Watson NE Jr 2001 Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942–946.
38.
Ryan WRFee WE JrLe QTPinto HA2005. Positron-emission tomography for surveillance of head and neck cancerLaryngoscope115645-650. 38. Ryan WR, Fee WE Jr, Le QT, Pinto HA 2005 Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 115:645–650.
39.
Tuttle RMTala HShah JLeboeuf RGhossein RGonen MBrokhin MOmry GFagin JAShaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging systemThyroid201341-1349. 39. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349.
40.
Brassard MBorget IEdet-Sanson AGiraudet ALMundler OToubeau MBonichon FBorson-Chazot FLeenhardt LSchvartz CDejax CBrenot-Rossi IToubert METorlontano MBenhamou ESchlumberger M2011. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patientsJ Clin Endocrinol Metab961352-1359. 40. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352–1359.
41.
Gould MKKuschner WGRydzak CEMaclean CCDemas ANShigemitsu HChan JKOwens DK2003. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysisAnn Intern Med139879-892. 41. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK, Owens DK 2003 Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139:879–892.
42.
Chen LLuo QShen YYu YYuan ZLu HZhu R2008. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinomaJ Nucl Med491952-1957. 42. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, Zhu R 2008 Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 49:1952–1957.
43.
Wong KKZarzhevsky NCahill JMFrey KAAvram AM2009. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinomaBr J Radiol82860-876. 43. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM 2009 Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol 82:860–876.
44.
Grewal RKTuttle RMFox JBorkar SChou JFGonen MStrauss HWLarson SMSchoder H2010. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancerJ Nucl Med511361-1367. 44. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, Strauss HW, Larson SM, Schoder H 2010 The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med 51:1361–1367.
45.
Wang WLarson SMTuttle RMKalaigian HKolbert KSonenberg MRobbins RJ2001. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodineThyroid111169-1175. 45. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11:1169–1175.
Information & Authors
Information
Published In
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published in print: February 2012
Published online: 1 February 2012
Published ahead of print: 6 January 2012
Topics
Authors
Disclosure Statement
The authors declare that no competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.